Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Dose dependence of the cytokinetic and cytotoxic effects of epirubicin in vitro

  • 61 Accesses

  • 13 Citations

Summary

CHO cells were exposed in vitro for 1 h to concentrations of 0.1–20 μg/ml of the cytostatic drug epirubicin. Population growth, survival fractions, cell-cycle-phase distribution, and BrdU incorporation were analyzed. A fraction of the cells showed a transitory cytostatic reaction at 1 μg/ml, and >99% of the cells were killed at 10 μg/ml. The survival curve was biphasic with a steep slope at concentrations of up to 5 μg/ml. Approximately 0.1% of the cells were resistant to higher concentrations of epirubicin. Bivariate DNA/BrdU flow cytometry revealed that the sensitive cells were blocked and probably killed in the G2M phase of the cell cycle.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Altavilla G, Adamo V, Alafaci E, Buemi B, Caristi B, Condemi G, Toscano G (1989) VP16, epirubicin and procarbazine in the treatment of advanced non-small-cell lung cancer. Tumori 51: 168

  2. 2.

    Baranco SC (1975) Review of the survival and cell kinetic effects of Adriamycin (NSC-123 127) on mammalian cells. Cancer Chemother Rep 6: 147

  3. 3.

    Baranco SC (1986) Cellular and molecular effects of Adriamycin on dividing and nondividing cells. In: Dethlefsen LA (ed) Cell cycle effect of drugs. Pergamon, Oxford, p 251

  4. 4.

    Bradley G, Juranka PF, Ling V (1988) Mechanism of multidrug resistance. Biochim Biophys Acta 948: 87

  5. 5.

    Braunschweiger PG, Schiffer LM (1980) Effect of Adriamycin on the cell kinetics of 13 762 rat mammary tumors and implications for therapy. Cancer Treat Rep 64: 3812

  6. 6.

    Cantoni O, Sestili P, Cattabeni F, Geroni C, Grandi M, Giuliani FC (1989) Cellular and molecular pharmacology of 4′-epidoxorubicin in HeLa cells. J Cancer Res Clin Oncol 115: 373

  7. 7.

    Cantoni O, Sestili P, Cattabeni F, Geroni C, Giuliani F (1990) Comparative effects of doxorubicin and 4′-epidoxorubicin on nucleic acid metabolism and cytotoxicity in a human tumor cell line. Cancer Chemother Pharmacol 27: 47

  8. 8.

    Gundersen S, Kvinnsland S, Klepp O, Lund E, Hst H (1990) Weekly Adriamycin registered vs 4-epidoxorubicin every second week in advanced breast cancer. A randomized trial. Eur J Cancer 26: 45

  9. 9.

    Heidemann E, Steinke B, Hartlapp J, Schumacher K, Possinger, Kunz S, Neeser E, Ingersleben G von, Hossfeld D, Waldmann R (1990) Randomized clinical trial comparing mitoxantrone with epirubicin and with doxorubicin, each combined with cyclophosphamide in the first-line treatment of patients with metastatic breast cancer. Onkologie 13: 24

  10. 10.

    Hemmer J (1990) Rapid in vitro bromodeoxyuridine labeling method for monitoring of therapy response in solid human tumors. Cytometry 11: 603

  11. 11.

    Kaye S, Merry S (1985) Tumour cell resistance to anthracyclines: a review. Cancer Chemother Pharmacol 14: 96

  12. 12.

    Kimler BF, Cheng CC (1982) Comparison of the effects of dihydroxyanthraquinone and Adriamycin on the survival of cultured Chinese hamster cells. Cancer Res 42: 3631

  13. 13.

    Kretzschmar A, Drings P (1990) Epirubicin weekly in combination chemotherapy with cyclophosphamide and vincristine in untreated small cell lung cancer. Onkologie 13: 141

  14. 14.

    Lopez M, Natali M, Lauro L di, Tonini G, Carpano S, Vici P, Conti EM (1990) 5-Fluorouracil, epirubicin, and BCNU (FEB) in advanced measurable gastric cancer. Am J Clin Oncol 13: 204

  15. 15.

    Roth A, Zupanc D, Luetic J, Kaloric K (1990) Open phase II with 5-fluorouracil, 4′epidoxorubicin and mitomycin C (FEM) in advanced gastric cancer. Tumori 75: 51

  16. 16.

    Tobey RA, Chrissman HA, Oka MS (1976) Arrested and cycling CHO cells as a kinetic model: studies with Adriamycin. Cancer Treat Rep 60: 1829

  17. 17.

    Toma S, Coialbu T, Biassoni L, Folce U, Gatti C, Canavese G, Giacchero A, Rosso R (1990) Epidoxorubicin plus ifosfamide in advanced and/or soft-tissue sarcoma. Cancer Chemother Pharmacol 26: 453

  18. 18.

    Torti FM, Bristow MM, Lum BL, Carter SK, Howes AE, Aston DA, Brown BW, Hannigan JF, Meyers FJ, Mitchell EP (1986) Cardiotoxicity of epirubicin and doxorubicin: assessment by endomyocardial biopsy. Cancer Res 46: 3722

  19. 19.

    Van der Vijgh WJF, Maessen PA, Pinedo HM (1990) Comparative metabolism and pharmacokinetics of doxorubicin and 4′-epidoxorubicin in plasma, heart and tumor of tumor-bearing mice. Cancer Chemother Pharmacol 26: 9

  20. 20.

    Zante J, Schumann J, Barlogie B, Göhde W, Büchner T (1976) New preparation and staining procedure for specific and rapid analysis of DNA distribution. In: Göhde W, Schumann J, Büchner T (eds) Pulse cytophotometry. European Press Medica, Ghent, p 97

Download references

Author information

Correspondence to Detlef Bartkowiak.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Bartkowiak, D., Hemmer, J. & Röttinger, E. Dose dependence of the cytokinetic and cytotoxic effects of epirubicin in vitro. Cancer Chemother. Pharmacol. 30, 189–192 (1992). https://doi.org/10.1007/BF00686310

Download citation

Keywords

  • Cell Cycle
  • Flow Cytometry
  • Cancer Research
  • Population Growth
  • Survival Curve